Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions By Ogkologos - June 23, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source RELATED ARTICLESMORE FROM AUTHOR No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin MOST POPULAR Can Some People with Breast Cancer Safely Skip Lymph Node Radiation? January 23, 2024 Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... March 27, 2021 FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer March 10, 2021 Cancer Research UK honours Her Majesty The Queen, the charity’s Patron September 8, 2022 Load more HOT NEWS The (un)usual suspects – how early detection research embraces interdisciplinary science Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... Breaking down the new standards for cancer care proposed by NHS...
